Diligence memo · auto-generated · as of July 2, 2026
Verseon Corp
Verseon Corp looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Verseon Corp operates in Pharmaceuticals, based in FREMONT.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Verseon Corp has raised $25M in disclosed capital across 6 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $12M on 2009-09-16.
Most recent recorded round closed around 2019-03-18.
Valuation (modeled)modeled
Provath models Verseon Corp at approximately $3.1M (range $116K–$17M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.02× the median modeled value of Series A Pharmaceuticals companies in 2019–2021 (76 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 32 months.
Last raise 7.3 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 4.4× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 69% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 6% of those peers.
Closest niche peers: Xynomic Pharmaceuticals Holdings, Inc., Honest Globe Inc., Athenen Therapeutics, Inc., Zomedica Pharmaceuticals Corp., CerSci Therapeutics Inc..
Peoplefiled
5 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.